Poolbeg Pharma PLC
POLB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £26 | £101 | £13 | £13 |
| Gross Profit | -£26 | -£101 | -£13 | -£13 |
| % Margin | – | – | – | – |
| R&D Expenses | £527 | £682 | £0 | £812 |
| G&A Expenses | £0 | £3,145 | £1 | £1 |
| SG&A Expenses | £2,005 | £3,145 | £1 | £1,968 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £1,967 |
| Other Operating Expenses | £0 | £16 | £2,800 | £13 |
| Operating Expenses | £2,532 | £3,843 | £2,801 | £2,793 |
| Operating Income | -£2,558 | -£3,843 | -£2,814 | -£2,793 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | £325 | £182 | £531 | £99 |
| Pre-Tax Income | -£2,233 | -£3,661 | -£2,283 | -£2,694 |
| Tax Expense | -£55 | £129 | -£25 | -£574 |
| Net Income | -£2,178 | -£3,532 | -£2,258 | -£2,120 |
| % Margin | – | – | – | – |
| EPS | -0.004 | -0.007 | -4.52 | -4.3 |
| % Growth | 39.4% | 99.8% | -5.1% | – |
| EPS Diluted | -0.004 | -0.007 | -4.52 | -4.28 |
| Weighted Avg Shares Out | 506,537 | 497,464 | 500 | 493 |
| Weighted Avg Shares Out Dil | 506,537 | 500,000 | 500 | 495 |
| Supplemental Information | – | – | – | – |
| Interest Income | £116 | £182 | £246 | £262 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £26 | £101 | £13 | £13 |
| EBITDA | -£2,207 | -£3,481 | -£2,270 | -£2,681 |
| % Margin | – | – | – | – |